Archives

  • 2026-11
  • 2026-10
  • 2026-09
  • 2026-08
  • 2026-07
  • 2026-06
  • 2026-05
  • 2026-04
  • 2026-03
  • 2026-02
  • 2026-01
  • 2025-12
  • 2025-11
  • 2025-10
  • YC-1 Product Overview and Evidence Limits

    2026-10-09

    YC-1, also identified as 5-(1-benzyl-1H-indazol-3-yl)furan-2-yl)methanol, is listed by APExBIO as SKU B7641. The product page reports the molecular formula C19H16N2O2 and a molecular weight of 304.34. APExBIO describes it as a crystalline small molecule supplied for scientific research use and links the compound with soluble guanylyl cyclase (sGC) and HIF-1α-related research: YC-1 (5-(1-benzyl-1H-indazol-3-yl)furan-2-yl)methanol.

    Conceptual research scope

    In the supplied product description, YC-1 is presented in the context of inhibition of hypoxia-inducible factor 1 transcriptional activity, hypoxia biology, cancer research, tumor angiogenesis inhibition, and apoptosis and cancer biology research. The description also characterizes YC-1 as an HIF-1α inhibitor and an YC-1 soluble guanylyl cyclase activator for research. These statements define the marketed conceptual scope; they do not independently establish mechanism, efficacy, selectivity, or reproducibility.

    Evidence limitations

    No matched paper evidence is available for this overview. Therefore, the product description cannot substantiate reported cellular, animal, or clinical outcomes, and no therapeutic or diagnostic applicability should be inferred. This overview is limited to documented product identity and supplier-described research context; it does not provide experimental recommendations or validate performance in any specific model.